Progynova dragee 2mg №21

Active ingredient

Dragee: 1 pill contains estradiol valerate 2 mg;
Excipients: lactose monohydrate, corn starch, polyvidone 25000, talc, Magnesium stearate, sucrose, polyvidone 700000, macrogol 6000, Calcium carbonate precipitate, 85% glycerin, titanium dioxide, yellow iron oxide pigment, indigo carmine varnish and mountain wax;
21 pieces in a blister with a calendar scale, 1 blister in a carton box.

P №013529/01 08.17.04

Mechanism of action

Estrogenic drug - 17 beta-estradiol is identical to endogenous estradiol (which is formed in the body of women, starting from the first menstruation up to the menopause), produced by the ovaries.
Fills the lack of endogenous estrogen, lowers LDL cholesterol in the blood. Suppresses somatic, mental and other climacteric symptoms during periods of pre- and postmenopause or after oophorectomy; prevents bone loss and osteoporosis.

Indications and usage

Estrogen deficiency (postmenopausal period, oophorectomy, radiation castration), accompanied by vasomotor symptoms: hot flashes, sweating, sleep disturbances, depressive states, irritability, headache, dizziness, hyperesthesia of the bladder, degenerative changes of the skin and mucous membranes; prevention of osteoporosis in menopause.

Contraindications

Hypersensitivity, pregnancy, breastfeeding, severe liver dysfunction, Dubin-Johnson and Rotor syndromes, liver tumors and thromboembolic processes (including history), breast cancer, existing or suspected tumors that are sensitive to sex steroid hormones, severe hypertriglyceridemia, vaginal bleeding of unknown origin.

Dosage and Administration

The drug should be taken orally, after eating, without chewing, drinking a small amount of liquid.
Primary and secondary estrogen deficiency - 1-2 mg once a day for 3 weeks, then a break (1 week), and then continue the treatment.Maintenance dose is selected by titration to the minimum effective.
Typically, the drug is used up to 6 months, after which a medical examination is carried out to decide whether to continue estrogen replacement therapy. In women undergoing hysterectomy (ovariectomy), as well as in the postmenopausal period, treatment can be initiated on any day; In menstruating patients, treatment should begin on the 5th day of the menstrual cycle.

Adverse reactions

Headache, nausea, uterine bleeding, exacerbation of endometriosis, dyspepsia, feeling of tension in the mammary glands, weight gain, stimulation of the growth of hormone-dependent neoplasms, skin pigmentation in the form of spots.

Pregnancy and breastfeeding

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Special notes

With care prescribed for benign tumors, with herpes in history and patients over 60 years.

Drug interactions

Enhances the effects of gestagens and gonadotropins.

Storage conditions

Store at room temperature out of the reach of children.